Direct oral anticoagulants in the treatment of portal vein thrombosis: a therapeutic review

Despite being unlicensed for the treatment of portal vein thrombosis, direct oral anticoagulants may offer benefits over oral vitamin K antagonists and low molecular weight heparins. Here, the current evidence-base related to their use for this indication is evaluated to inform and educate healthcar…
Published: 8 December 2021